AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10832472
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg IVIG on the first day of life
Trial: 3371858
Drug: Betamethasone (6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (6.0 mg for the first 5 days, 4.5 mg for the following week, and then 3.0 mg)
Trial: 27039954
Drug: Naloxone (opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (opioid blocker)
Trial: 26349124
Drug: Oral-B Pulsar
RxNorm normalized name: Oral-B Pulsar 3D White Luxe Pulsar Toothbrush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B Pulsar manual brush (OBP)
Trial: 21664512
Drug: Mifepristone 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 5 mg daily for three cycles
Trial: 21664512
Drug: Mifepristone 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 5 mg every other day for three cycles
Trial: 18294410
Drug: Intraperitoneal tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal tramadol 100 mg
Trial: 11121720
Drug: Copper supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper supplementation (3 or 6 mg/d)
Trial: 11121720
Drug: Control diets
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diets (0.7/1.6/6.0 mg/d)
Trial: 8594164
Drug: Short-term drug
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term drug abuse treatment (23-day duration)
Trial: 1695312
Drug: Isradipine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (7.5 mg b.i.d.)
Trial: 293493
Drug: Continuing therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuing therapy for a total of six years
Trial: 293493
Drug: Stopping therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopping therapy after three years
Trial: 31349945
Drug: CoQ10 and
RxNorm normalized name: Daily Energy Vitamin B12 + CoQ10 and Goji Berry Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 and Vitamin E (alone or in combination)
Trial: 24246597
Drug: Kangaroo care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangaroo care (KC) for 2 hours daily between days of life 5 to 10
Trial: 19349317
Drug: Intravenous reconstituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous reconstituted HDL (rHDL: 80 mg/kg over 4 hours)
Trial: 9322632
Drug: Misoprostol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (25 microgram tablets every 4 hours for a maximum of six doses)
Trial: 9322632
Drug: Dinoprostone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone (10 mg vaginal insert for a maximum of 24 hours)
Trial: 7993573
Drug: High-dose OKT3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose OKT3 (5 mg)
Trial: 3054035
Drug: Nalidixic acid
RxNorm normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nalidixic acid (55 mg/kg/day for 5 days)
Trial: 28096757
Drug: PWS +
RxNorm normalized name: Pulsed Wave Stimulation Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PWS + S (pre-workout dietary supplement with synephrine)
Trial: 16797309
Drug: Vardenafil treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil treatment
Trial: 11023085
Drug: BCAA 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA 150 g daily
Trial: 11023085
Drug: Standardized diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized diet with 80 g protein daily
Trial: 9407258
Drug: Gamma-oryzanol supplementation
RxNorm normalized name: GAMMA ORYZANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma-oryzanol supplementation (500 mg.day-1)
Trial: 3918190
Drug: Oral penicillin
RxNorm normalized name: penicillin G Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral penicillin for 72 hours
Trial: 30252895
Drug: Active transcranial
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active transcranial pulsed electromagnetic field treatment (squared bipolar 3 ms pulses, 50 Hz) for 30 min/day for 8 weeks
Trial: 30252895
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 30 min/day for 8 weeks
Trial: 27209465
Drug: Pasireotide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 600 μg sc bid
Trial: 27209465
Drug: Pasireotide 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 900 μg sc bid
Trial: 15130080
Drug: Oral Balance
RxNorm normalized name: Biotene Oral Balance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Balance gel (used three times a day for 90 days)
Trial: 15130080
Drug: gel placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel placebo (used three times a day for 90 days)
Trial: 9164361
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 100 micrograms once daily for 4 weeks
Trial: 8431629
Drug: Hourly pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hourly pain assessments for 48 hours using VAS
Trial: 2959626
Drug: Antitissue immunoglobulins
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antitissue immunoglobulins (Sérocytol Neuro‐Vasculaire) administered by intradermal injections
Trial: 362293
Drug: Immuno-chemotherapy (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immuno-chemotherapy (1 mg Corynebacterium parvum i.v. on days 1-4 + MeCCNU 200 mg/m2 on day 8, repeated every 7 weeks)
Trial: 362293
Drug: Chemotherapy (MeCCNU,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (MeCCNU, 200 mg/m2, given orally every 8 weeks)
Trial: 362293
Drug: Immuno-chemotherapy (C.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immuno-chemotherapy (C. parvum + MeCCNU)
Trial: 362293
Drug: Chemotherapy (MeCCNU)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (MeCCNU)
Trial: 28345792
Drug: Basal-only insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal-only insulin (n=120)
Trial: 22152769
Drug: Bufei Yishen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bufei Yishen Granule combined with acupoint‐sticking therapy
Trial: 9625090
Drug: 600-mL preload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600-mL preload
Trial: 9625090
Drug: 300-mL preload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-mL preload
Trial: 9625090
Drug: 450-mL preload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450-mL preload
Trial: 21036173
Drug: PEG alfa-2a
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG alfa-2a (PEG-2a; 180 μg/1.73 m(2) body surface area, subcutaneously each week) and ribavirin (15 mg/kg orally in 2 doses daily)
Trial: 15252294
Drug: Acamprosate (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (0, 2, and 4 g, p.o.)
Trial: 11333096
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL fibrin sealant at axillary dissection site
Trial: 11333096
Drug: 16 mL
RxNorm normalized name: 16 ML Mvasi 25 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mL fibrin sealant at axillary dissection site and 8 mL at skin flap site
Trial: 8136395
Drug: Scopolamine and
RxNorm normalized name: butylscopolamine and analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine and morphine
Trial: 3027153
Drug: Nedocromil sodium,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium, 4 mg from a metered-dose inhaler
Trial: 3027153
Drug: Cromolyn sodium,
RxNorm normalized name: Cromolyn Sodium, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium, 20 mg from a Spinhaler
Trial: 24765899
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (ITM) 0 mg (control)
Trial: 23539257
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (ethinylestradiol 0.035 mg + norethisterone 1 mg)
Trial: 16931264
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL injection volume of peribulbar anesthesia
Trial: 16931264
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL injection volume of peribulbar anesthesia
Trial: 10973836
Drug: Eptifibatide infusion
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide infusion for up to 72 to 96 hours
Trial: 29600482
Drug: Placebo (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.4 mL·kg‐1 of 0.9% saline)
Trial: 26658804
Drug: Lactulose oral
RxNorm normalized name: lactulose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose oral solution and polyethylene glycol electrolyte powder
Trial: 20499122
Drug: Ultrasound and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound and standard physical therapy (group III)
Trial: 20499122
Drug: Sham ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ultrasound in addition to standard physical therapy (group II)
Trial: 20499122
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy including hot pack and exercise program (group I)
Trial: 17110604
Drug: GW501516 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW501516 10 mg
Trial: 17110604
Drug: GW501516 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW501516 2.5 mg
Trial: 10419240
Drug: Cornstarch (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cornstarch (0.3 g/kg)
Trial: 7593726
Drug: Clomipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (150 mg daily)
Trial: 7205167
Drug: Cephalexin administered
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin administered twice a day
Trial: 7205167
Drug: Cephalexin administered
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin administered four times a day
Trial: 30094983
Drug: Herbal cake-partitioned
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal cake-partitioned moxibustion combined with Rhinocort nasal spray (2 jets/day for each nostril, 64 µg/jet) for 8 weeks
Trial: 30094983
Drug: Rhinocort nasal
RxNorm normalized name: Rhinocort Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhinocort nasal spray (2 jets/day for each nostril, 64 µg/jet) for 8 weeks
Trial: 27322311
Drug: Omegaven(®) 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omegaven(®) 10% 100 mL/day for five days postoperatively
Trial: 17767511
Drug: ASA 1000
RxNorm normalized name: Canasa 1000mg Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA 1000 mg
Trial: 16582548
Drug: MORA bioresonance
RxNorm normalized name: OCTINOXATE 0.0664 g in 1 g / OXYBENZONE 0.0151 g in 1 g TOPICAL LIPSTICK [ESIKA HYDRACOLOR 2 IN 1 SPF 25 (MORA GLAM) - BROWN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MORA bioresonance therapy
Trial: 57244
Drug: Thiacetazone 150
RxNorm normalized name: Thioacétazone
DrugBank: Amithiozone (DB12829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiacetazone 150 mg with Isoniazid 300 mg once daily
Trial: 57244
Drug: Paraaminosalicyclic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paraaminosalicyclic acid 12 gm with Isoniazid 300 mg daily in divided doses
Trial: 27266883
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (physical therapy only)
Trial: 19411388
Drug: naproxcinod 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxcinod 750 mg bid
Trial: 20828790
Drug: naproxcinod 375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxcinod 375 mg bid
Trial: 18708688
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (CR: 0.25 g/kg lean-tissue mass for 7 days; 0.06 g/kg lean-tissue mass for 49 days; n=22, 12 males, 10 females)
Trial: 11427833
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion with propofol/alfentanil (Group II)
Trial: 11427833
Drug: Nurse-administered midazolam/meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-administered midazolam/meperidine (Group III)
Trial: 9566014
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic injection (LA)
Trial: 3142349
Drug: Erythromycin ethylsuccinate
RxNorm normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin ethylsuccinate (600 mg)
Trial: 25279807
Drug: QAM dosing
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAM dosing of extended-release hydromorphone
Trial: 25279807
Drug: QPM dosing
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QPM dosing of extended-release hydromorphone
Trial: 23102797
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 800 mcg
Trial: 21903473
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy (bolus and infusional fluorouracil plus leucovorin, followed by oxaliplatin and irinotecan)
Trial: 21903473
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (FOLFOX6 followed by FOLFIRI)
Trial: 16352689
Drug: rosiglitazone (RSG;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (RSG; 8 mg/d; n = 13)
Trial: 31283521
Drug: Aspirin desensitization
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin desensitization combined with long-term Aspirin therapy
Trial: 29425912
Drug: Low-dose prophylaxis
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prophylaxis antibiotics
Trial: 29425912
Drug: Antibiotics for
RxNorm normalized name: ANTIBIOTICS FOR TOPICAL USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for urinary tract infection treatment
Trial: 27168265
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg every other week (following 80 mg at week 0)
Trial: 15229059
Drug: Reboxetine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (8 mg/day)
Trial: 7512433
Drug: Methylprednisolone 20
RxNorm normalized name: methylprednisolone 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 20 mg
Trial: 25195590
Drug: Every 2
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 2 weeks cetuximab (500 mg/m²)
Trial: 25195590
Drug: Weekly cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly cetuximab (250 mg/m²)
Trial: 23281805
Drug: Paclitaxel (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (200 mg/m2, day 1) plus carboplatin (AUC 6 mg/mL/min, day 1) every 3 weeks (Arm A)
Trial: 23281805
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg/m2, days 1 and 8) plus carboplatin (AUC 5 mg/mL/min, day 1) every 3 weeks (Arm B)
Trial: 21668751
Drug: IV ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketamine infusion (2 µg/kg/min)
Trial: 21668751
Drug: IV ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketamine infusion
Trial: 18267006
Drug: Interferon gamma
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon gamma (1 x 106 IU recombinant human IFN gamma intramuscularly, daily for one month and then three times per week up to 6 months)
Trial: 17087052
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA)-rich fish oil-fortified drink (0.60 g EPA + 0.26 g docosahexaenoic acid/d) for 12 weeks
Trial: 11892888
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of melatonin
Trial: 31452471
Drug: PROPER intervention
RxNorm normalized name: Propel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PROPER intervention - structured and biannually repeated multidisciplinary medication review
Trial: 19335686
Drug: Topical betamethasone
RxNorm normalized name: betamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betamethasone
Trial: 16684385
Drug: Daily supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplements for 5 days a week
Trial: 16684385
Drug: Weekly supplements
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly supplements
Trial: 11958389
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human bFGF administered weekly by intravenous infusions of 2 microg/kg for 6 weeks (total dose 12 microg/kg)
Trial: 9042989
Drug: Lactulose 20
RxNorm normalized name: lactulose 20000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose 20 g t.d.s. for 15 days
Trial: 9042989
Drug: Lactose 20
RxNorm normalized name: lactose 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose 20 g t.d.s. as placebo
Trial: 7706699
Drug: 20mg lisinopril
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg lisinopril
Trial: 25555797
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl (54 μg per spray, mean total dose 734 μg, duration of use 3.5 h)
Trial: 23132474
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg intravenously 1 hour prior to subarachnoid block
Trial: 23132474
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (placebo) 2 ml intravenously 1 hour prior to subarachnoid block
Trial: 17697450
Drug: OROS hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS hydromorphone in the treatment of chronic low back pain (CLBP)
Trial: 17697450
Drug: OROS hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS hydromorphone in the treatment of pain associated with chronic osteoarthritis (OA)
Trial: 15138569
Drug: 13‐cRA at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13‐cRA at a dose of 0.5 mg/kg per day per os
Trial: 9690954
Drug: Tucaresol 200
RxNorm normalized name: Tucaresol
DrugBank: Tucaresol (DB13027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tucaresol 200 mg after overnight fast
Trial: 9690954
Drug: Tucaresol 200
RxNorm normalized name: Tucaresol
DrugBank: Tucaresol (DB13027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tucaresol 200 mg after ingestion of a standard breakfast
Trial: 9690954
Drug: Tucaresol 200
RxNorm normalized name: Tucaresol
DrugBank: Tucaresol (DB13027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tucaresol 200 mg in females
Trial: 9690954
Drug: Tucaresol 200
RxNorm normalized name: Tucaresol
DrugBank: Tucaresol (DB13027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tucaresol 200 mg in males
Trial: 7659481
Drug: Whole-cell pertussis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-cell pertussis vaccine (DTP)
Trial: 2568785
Drug: Iotrolan 240
RxNorm normalized name: IOTROLAN 240MG/ML INJ INTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iotrolan 240 mg I/ml
Trial: 2568785
Drug: Iotrolan 300
RxNorm normalized name: Iotrolan
DrugBank: Iotrolan (DB09487)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iotrolan 300 mg I/ml
Trial: 409803
Drug: Clonazepam added
RxNorm normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonazepam added to treatment
Trial: 31880966
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m2 plus bevacizumab 15 mg/kg
Trial: 25084742
Drug: Miconazole mucoadhesive
RxNorm normalized name: Miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole mucoadhesive buccal tablet (MBT)
Trial: 25084742
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral amphotericin B suspensions
Trial: 23535839
Drug: Eight cycles
RxNorm normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight cycles of anthracycline-based chemotherapy
Trial: 21707626
Drug: Regular monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular monthly continuing education class (Control)
Trial: 16432076
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy (HDT) with melphalan 140 mg/m2 plus total-body irradiation 12 Gy